Breast Cancer Anti-Estrogen Resistance 1 (BCAR1) Antibody

Product specifications

Primary Antibodies

Breast Cancer Anti-Estrogen Resistance 1 (BCAR1)

Mouse

Human

WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.

Monoclonal

Unconjugated

Purified by Protein A and Protein G affinity chromatography.

1 ml

Liquid

WB, IHC, IF/ICC

0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.

Please enquire.

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

No

BCAR1, CAS, CAS1, CASS1, CRKAS, P130Cas, Cas family scaffolding protein, Cas family scaffold protein, BCAR1 scaffold protein, Cas family member

Antibody anti-BCAR1

RUO

Descripción

BCAR1, also known as the Breast Cancer Anti-Estrogen Resistance 1 protein, is an important protein involved in the development of resistance to anti-estrogen therapies, such as tamoxifen, used in the treatment of estrogen receptor-positive breast cancer. BCAR1 plays a crucial role in cell signaling pathways that regulate cell survival, proliferation, and resistance to apoptosis. It is often upregulated in breast cancer cells that become resistant to estrogen receptor-targeted therapies. The protein interacts with several other signaling molecules involved in the regulation of cell motility and survival, contributing to the metastatic potential of breast cancer cells. Understanding BCAR1’s role in therapy resistance has significant implications for developing alternative therapeutic strategies for patients with estrogen receptor-positive breast cancer who develop resistance to current treatments.

Related Products

Human BCAR1 (Breast Cancer Anti Estrogen Resistance 1) ELISA Kit

Ver Producto

BCAR1 antibody

Ver Producto

BCAR1 antibody

Ver Producto